tenofovir alafenamide + VIR-2218 + selgantolimod + nivolumab

This is a **combination investigational regimen** composed of the following agents: - **tenofovir alafenamide**: a small molecule nucleotide reverse transcriptase inhibitor used in the treatment of chronic hepatitis B and HIV[1][3][5]. It works by inhibiting the hepatitis B viral polymerase and the HIV-1 reverse transcriptase, causing DNA chain termination and inhibition of viral replication[1][3]. - **VIR-2218**: a small interfering RNA targeting HBV transcripts, designed to reduce all species of HBV RNA and antigens (including HBsAg). - **selgantolimod** (GS-9688): a selective Toll-like receptor 8 (TLR8) agonist that stimulates innate immune responses by inducing cytokines and chemokines; developed for chronic hepatitis B[2][4]. - **nivolumab**: a monoclonal antibody targeting and inhibiting the immune checkpoint protein Programmed cell death protein 1 (PD-1), thereby enhancing antitumor and antiviral T-cell activity. This regimen is under investigation for its potential in functional cure of chronic hepatitis B, leveraging **direct antiviral approaches and immune activation**. Developers of agents in this combination include Gilead Sciences (tenofovir alafenamide, selgantolimod), Vir Biotechnology (VIR-2218), and Bristol Myers Squibb (nivolumab).

Brand names

Vemlidy (tenofovir alafenamide)Descovy (tenofovir alafenamide combination)Biktarvy (tenofovir alafenamide combination)Genvoya (tenofovir alafenamide combination)Odefsey (tenofovir alafenamide combination)Symtuza (tenofovir alafenamide combination)

Other names

tenofovir alafenamide fumarateGS-7340GS7340GS 7340GS-9688 (selgantolimod)